Literature DB >> 20931215

Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy.

Roberto Gallego-Pinazo1, Rosa Dolz-Marco, Diamar Pardo-López, J Fernando Arevalo, Manuel Díaz-Llopis.   

Abstract

AIM: To evaluate the efficacy of intravitreal injections of ranibizumab in adult-onset foveomacular vitelliform dystrophy (AOFVD).
METHODS: Six female patients were misdiagnosed in the office as occult choroidal neovascularization due to AMD, and scheduled for 3-monthly intravitreal injections of ranibizumab. One month after the third injection, all patients underwent further examinations consisting of visual acuity, optical coherence tomography, Indocyanine Green angiography, electrophysiological tests (electroretinogram and electrooculogram), and an exhaustive familial history of macular diseases. Cases were followed-up every 6 weeks since the formal diagnose of AOFVD was evidenced.
RESULTS: The mean BCVA improved from 0.36 ± 0.1 at baseline to 0.56 ± 0.1 (p = 0.038). No significant change was evidence in the SD-OCT thickness analysis. Metamorphopsia disappeared completely in all cases after the first injection. No familial history was evidenced.
CONCLUSIONS: Ranibizumab intravitreal injections are effective in the short-term BCVA improvement in patients with AOFVD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20931215     DOI: 10.1007/s00417-010-1536-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  7 in total

1.  Adult-onset foveomacular vitelliform dystrophy: a study by optical coherence tomography.

Authors:  Nathanael Benhamou; Eric H Souied; Ricky Zolf; Florence Coscas; Gabriel Coscas; Gisele Soubrane
Journal:  Am J Ophthalmol       Date:  2003-03       Impact factor: 5.258

Review 2.  [Macular vitelliform degeneration in adults. Retrospective study of a series of 85 patients].

Authors:  A Glacet-Bernard; G Soubrane; G Coscas
Journal:  J Fr Ophtalmol       Date:  1990       Impact factor: 0.818

3.  Spectral domain optical coherence tomography in a patient with adult-onset vitelliform dystrophy treated with intravitreal bevacizumab.

Authors:  Joo Yong Lee; Jongyoon Lim; Hyewon Chung; June-Gone Kim; Young Hee Yoon
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2009 May-Jun

4.  Monozygotic twin sisters with adult vitelliform macular dystrophy.

Authors:  S Y Cohen; P Chretien; C Cochard; G J Coscas
Journal:  Am J Ophthalmol       Date:  1993-08-15       Impact factor: 5.258

5.  Foveomacular dystrophy.

Authors:  J I Lim; C Enger; S L Fine
Journal:  Am J Ophthalmol       Date:  1994-01-15       Impact factor: 5.258

6.  Macular disease resembling adult foveomacular vitelliform dystrophy in older adults.

Authors:  D B Burgess; R J Olk; L M Uniat
Journal:  Ophthalmology       Date:  1987-04       Impact factor: 12.079

7.  Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report.

Authors:  J A Montero; J M Ruiz-Moreno; C De La Vega
Journal:  Eur J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 2.597

  7 in total
  4 in total

Review 1.  Gene therapy for PRPH2-associated ocular disease: challenges and prospects.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-28       Impact factor: 6.915

2.  Intravitreal ranibizumab in the treatment of butterfly-shaped pattern dystrophy associated with choroidal neovascularization: a case report.

Authors:  Theodoros Empeslidis; Athanasios Vardarinos; James Deane; Somnath Banerjee
Journal:  Case Rep Ophthalmol       Date:  2012-02-29

3.  RORγt Inhibitor-SR1001 Halts Retinal Inflammation, Capillary Degeneration, and the Progression of Diabetic Retinopathy.

Authors:  Thomas E Zapadka; Sarah I Lindstrom; Brooklyn E Taylor; Chieh A Lee; Jie Tang; Zakary R R Taylor; Scott J Howell; Patricia R Taylor
Journal:  Int J Mol Sci       Date:  2020-05-17       Impact factor: 5.923

4.  Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid.

Authors:  Joseph Juliano; Sagar Patel; Hossein Ameri
Journal:  J Ophthalmic Vis Res       Date:  2021-10-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.